Our data demonstrated for the first time that the bioactive peptide G1dP3 could sensitize RA synovial fibroblasts to ferroptotic cell death via a p53/SLC7A11 axis-dependent mechanism, thereby providing novel opportunities and future directions for RA treatment. This evidence concerns the gene SLC7A11 and rheumatoid arthritis.